Close Menu

NEW YORK – Accelerate Diagnostics said on Wednesday that it has received 510(k) clearance from the US Food and Drug Administration for enhancements to the Accelerate Pheno system.

The additions improve the system's performance and expand its antimicrobial susceptibility testing menu for bloodstream infections. Specifically, the new products improve susceptibility testing performance for four antibiotics used to treat Pseudomonas aeruginosa and add the combination of P. aeruginosa and aztreonam to the Accelerate PhenoTest BC kit testing panel.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.